Blog
RSS FeedPosted by Michael Wonder on 04 Jul 2016
NICE backs Ferring’s Firmagon
4 July 2016 - Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring's Firmagon ...
Posted by Michael Wonder on 30 Jun 2016
Brexit could boost drug costs for Britain’s National Health Service
29 June 2016 - Sharp fall in pound is hurting traders that sell cut-price drugs to the NHS after importing them. ...
Posted by Michael Wonder on 24 Jun 2016
NICE publishes appraisal consultation for osimertinib mesylate (Tagrisso) for patients with non-small-cell lung cancer
24 June 2016 - NICE has published an appraisal consultation for AstraZeneca's Tagrisso. ...
Posted by Michael Wonder on 23 Jun 2016
New guidance from NICE recommends Humira (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition
22 June 2016 - AbbVie today announced that the NICE has published single technology appraisal guidance for the only licensed ...
Posted by Michael Wonder on 22 Jun 2016
NICE gives conditional backing for GSK’s Benlysta in lupus
22 June 2016 - NICE has today published final guidance which recommends UK pharma major GlaxoSmithKline’s Benlysta (belimumab) for treating systemic ...
Posted by Michael Wonder on 22 Jun 2016
UK drugs watchdog NICE approves five new treatments in coup for big pharma
22 June 2016 - The UK agency in charge of deciding which drugs the NHS will pay for has approved five ...
Posted by Michael Wonder on 18 Jun 2016
Drug combination for treating skin cancer approved for NHS use
17 June 2016 - Medicines regulator NICE moves at record speed to approve nivolumab for use with ipilimumab in melanoma patients. ...
Posted by Michael Wonder on 17 Jun 2016
Cost of cystic fibrosis treatment too high for benefit offered, says NICE
17 June 2016 - NICE has said it will not be able to recommend Orkambi (lumacaftor with ivacaftor, Vertex Pharmaceuticals) for ...
Posted by Michael Wonder on 16 Jun 2016
NICE publishes appraisal consultation for cobimetinib hemifumarate (Cotellic) for patients with malignant melanoma
16 June 2016 - NICE has published an appraisal consultation for Roche's cobimetinib hemifumarate (Cotellic). ...
Posted by Michael Wonder on 16 Jun 2016
Updated NICE quality standard identifies areas for breast cancer improvement
15 June 2016 - NICE’s latest quality standard published today says people who have been diagnosed with a type of early ...
Posted by Michael Wonder on 14 Jun 2016
NICE recommends laser device to help thousands of men with an enlarged prostate
14 June 2016 - Thousands of men could benefit from laser treatment for an enlarged prostate as recommended in new guidance ...
Posted by Michael Wonder on 09 Jun 2016
NICE publishes second appraisal consultation for Nucala (mepolizumab)
9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab). ...
Posted by Michael Wonder on 09 Jun 2016
NICE’s Eylea guideline ‘out of touch with clinical practice’
9 June 2016 - Bayer says it is disappointed that NICE is supporting NHS use of anti-VEGF therapy Eylea to treat ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for crizotinib (Xalkori) for patients with non-small-cell lung cancer
1 June 2016 - NICE has published an appraisal consultation document for crizotinib (Xalkori) for use by patients with non-small-cell ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for pirfenidone (Esbriet) for patients with idiopathic pulmonary fibrosis
3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic ...